NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 14 04:00PM ET
18.55
Dollar change
-5.33
Percentage change
-22.30
%
Index- P/E- EPS (ttm)-17.96 Insider Own0.00% Shs Outstand0.68M Perf Week29.54%
Market Cap12.68M Forward P/E- EPS next Y-10.08 Insider Trans- Shs Float0.68M Perf Month157.64%
Enterprise Value12.03M PEG- EPS next Q-25.14 Inst Own2.11% Short Float3.00% Perf Quarter276.07%
Income-9.72M P/S- EPS this Y-218.03% Inst Trans- Short Ratio0.03 Perf Half Y164.25%
Sales0.00M P/B15.56 EPS next Y82.68% ROA-140.10% Short Interest0.02M Perf YTD191.67%
Book/sh1.19 P/C16.91 EPS next 5Y28.82% ROE-190.70% 52W High28.60 -35.14% Perf Year136.01%
Cash/sh1.10 P/FCF- EPS past 3/5Y20.08% 27.29% ROIC-1366.39% 52W Low4.92 277.22% Perf 3Y-37.07%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility34.76% 25.00% Perf 5Y-83.51%
Dividend TTM- EV/Sales- EPS Y/Y TTM4.37% Oper. Margin- ATR (14)3.98 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.34 Sales Y/Y TTM- Profit Margin- RSI (14)60.35 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.34 EPS Q/Q6.92% SMA2061.47% Beta1.35 Target Price20.00
Payout- Debt/Eq0.15 Sales Q/Q- SMA50123.46% Rel Volume0.28 Prev Close23.88
Employees6 LT Debt/Eq0.09 EarningsMay 13 BMO SMA200165.17% Avg Volume691.51K Price18.55
IPONov 14, 2017 Option/ShortNo / Yes EPS/Sales Surpr.-440.14% - Trades Volume194,352 Change-22.30%
Date Action Analyst Rating Change Price Target Change
Jul-08-25Upgrade D. Boral Capital Hold → Buy $20
Feb-12-21Initiated Ladenburg Thalmann Buy $7
Jul-09-25 07:50AM
07:20AM
Jul-07-25 07:45AM
Jun-30-25 07:45AM
Jun-26-25 08:00AM
08:30AM Loading…
Jun-11-25 08:30AM
Jun-05-25 09:00AM
Jun-02-25 09:00AM
May-13-25 08:00AM
Apr-28-25 08:45AM
Apr-10-25 05:43AM
Mar-31-25 08:30AM
Mar-28-25 03:39AM
Mar-03-25 08:00AM
Feb-14-25 09:00AM
09:00AM Loading…
Feb-11-25 09:00AM
Jan-13-25 09:00AM
Dec-10-24 09:43AM
Dec-09-24 09:15AM
Nov-18-24 08:30AM
Nov-13-24 08:30AM
Nov-12-24 08:00AM
Nov-05-24 08:30AM
Oct-09-24 09:00AM
Sep-04-24 09:00AM
Aug-13-24 08:00AM
Jul-15-24 08:30AM
Jul-03-24 09:00AM
Jul-02-24 09:00AM
Jul-01-24 09:00AM
08:30AM Loading…
Jun-04-24 08:30AM
May-29-24 08:30AM
May-13-24 01:53PM
08:00AM
May-10-24 09:00AM
Apr-23-24 08:30AM
Apr-22-24 08:30AM
Mar-25-24 01:53PM
08:00AM
Mar-12-24 09:15AM
Feb-15-24 09:00AM
Jan-23-24 08:30AM
Jan-08-24 08:30AM
Dec-05-23 08:30AM
Nov-30-23 09:00AM
Nov-13-23 08:00AM
Nov-09-23 09:00AM
Nov-02-23 08:30AM
Oct-04-23 08:30AM
Sep-13-23 08:30AM
Sep-07-23 08:00AM
Sep-06-23 09:00AM
Sep-05-23 09:00AM
Aug-10-23 08:00AM
Jul-19-23 09:00AM
Jul-10-23 08:30AM
Jun-28-23 08:30AM
Jun-27-23 08:30AM
Jun-26-23 08:30AM
Jun-07-23 08:30AM
May-11-23 08:00AM
Apr-25-23 08:30AM
Mar-31-23 08:00AM
Feb-15-23 08:30AM
Feb-02-23 09:00AM
Jan-26-23 08:30AM
Nov-08-22 08:00AM
Oct-18-22 08:30AM
Sep-22-22 09:00AM
Sep-07-22 08:30AM
Aug-16-22 09:00AM
Aug-09-22 08:10AM
Jul-19-22 09:07AM
Jun-27-22 08:30AM
Jun-24-22 08:30AM
Jun-01-22 08:30AM
May-16-22 01:20PM
08:55AM
May-13-22 08:30AM
May-12-22 08:30AM
Apr-26-22 07:33AM
Apr-25-22 07:30AM
Apr-13-22 08:30AM
Mar-28-22 09:25AM
Mar-22-22 09:00AM
Mar-21-22 08:30AM
Mar-02-22 08:30AM
Jan-12-22 08:30AM
Jan-11-22 08:30AM
Jan-10-22 09:00AM
Jan-04-22 01:38PM
Nov-29-21 08:30AM
Nov-11-21 08:30AM
Nov-02-21 07:33AM
Sep-08-21 08:30AM
Aug-11-21 04:18PM
Aug-04-21 08:30AM
Jul-21-21 08:30AM
Jul-12-21 08:30AM
Jul-07-21 08:30AM
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.